COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS

被引：0
|
作者：
Cavusoglu, Y. [1 ]
Demir, O. [2 ]
Dinc, M. [3 ]
Ozsoy, A. [3 ]
Erdogan, A. [3 ]
Ozer, S. [4 ]
机构：
[1] Eskisehir Osmangazi Univ, Fac Med, Istanbul 34, Turkey
[2] Ankara Univ, Fac Med, Ankara, Turkey
[3] AstraZeneca, Istanbul, Turkey
[4] Omega CRO, Ankara, Turkey
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA166
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [31] Translating findings from the landmark DAPA-HF study: a multinational cost-effectiveness analysis of dapagliflozin in the treatment of heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Mcewan, P.
    Darlington, O.
    Jhund, P.
    Docherty, K.
    Bohm, M.
    Petrie, M.
    Bergenheim, K.
    Qin, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 272 - 273
  • [32] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [33] Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
    Lin, Xiaohui
    Lin, Minhua
    Liu, Maobai
    Huang, Weiying
    Nie, Xuekun
    Chen, Zichun
    Zheng, Bin
    JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1588 - 1597
  • [34] Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction
    Dixit, Neal M.
    Parikh, Neil U.
    Ziaeian, Boback
    Jackson, Nicholas
    Fonarow, Gregg C.
    JACC-HEART FAILURE, 2023, 11 (05) : 541 - 551
  • [35] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [36] The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial
    Booth, David
    Davis, Jason A.
    McEwan, Phil
    Solomon, Scott D.
    McMurray, John J. V.
    De Boer, Rudolf A.
    Comin-Colet, Josep
    Bachus, Erasmus
    Chen, Jieling
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1386 - 1395
  • [37] Effect of Time Since Heart Failure Diagnosis or Hospitalization on the Cost-effectiveness of Dapagliflozin in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
    Bhatt, Ankeet
    De Boer, Rudolf
    Booth, David
    Davis, Jason
    Chen, Jieling
    CIRCULATION, 2024, 150
  • [38] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
    Rane, A.
    Nechi, R. N.
    Imam, M.
    Zoni, C. R.
    Ndikumukiza, C.
    Karaye, I
    Yunusa, I
    Alanazi, A.
    VALUE IN HEALTH, 2023, 26 (06) : S99 - S99
  • [39] COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN SPAIN
    Lacasa, C.
    Obradors, M.
    Figueras, M.
    Perez-Alcantara, F.
    Brosa, M.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A650
  • [40] Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
    Tsutsui, Hiroyuki
    Sakamaki, Hiroyuki
    Momomura, Shin-ichi
    Sakata, Yasushi
    Kotobuki, Yutaro
    Linden, Stephan
    Idehara, Koki
    Nitta, Daisuke
    ESC HEART FAILURE, 2024, 11 (01): : 261 - 270
12345